View in EDS

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Saved in:
Bibliographic Details
Title: Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Authors: Niemann CU; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk., Munir T; St James's Hospital, Leeds, UK., Moreno C; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Owen C; Tom Baker Cancer Centre, Calgary, AB, Canada., Follows GA; Addenbrookes Hospital, Cambridge, UK., Benjamini O; Sheba Medical Center, Ramat Gan, Israel., Janssens A; UZ Leuven Gasthuisberg, Leuven, Belgium., Levin MD; Albert Schweitzer Hospital, Dordrecht, Netherlands., Robak T; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland., Simkovic M; 4th Department of Internal Medicine-Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic., Voloshin S; Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia., Vorobyev V; SP Botkin Moscow City Clinical Hospital, Moscow, Russia., Yagci M; Gazi Universitesi Tip Fakultesi, Ankara, Türkiye., Ysebaert L; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France., Qi K; Janssen Research & Development, Titusville, NJ, USA., Qi Q; Janssen Research & Development, Raritan, NJ, USA., Sinet P; Janssen Research & Development, Bridgewater, NJ, USA., Parisi L; Janssen Research & Development, Raritan, NJ, USA., Srinivasan S; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA, USA., Schuier N; Janssen Research & Development, Raritan, NJ, USA., Baeten K; Janssen Research & Development, Beerse, Belgium., Howes A; Janssen Research & Development, High Wycombe, UK., Caces DB; Janssen Research & Development, Raritan, NJ, USA., Kater AP; Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands.
Source: The Lancet. Oncology [Lancet Oncol] 2023 Dec; Vol. 24 (12), pp. 1423-1433. Date of Electronic Publication: 2023 Nov 06.
Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37944541
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Niemann+CU%22">Niemann CU</searchLink>; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk.<br /><searchLink fieldCode="AU" term="%22Munir+T%22">Munir T</searchLink>; St James's Hospital, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Moreno+C%22">Moreno C</searchLink>; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Owen+C%22">Owen C</searchLink>; Tom Baker Cancer Centre, Calgary, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Follows+GA%22">Follows GA</searchLink>; Addenbrookes Hospital, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Benjamini+O%22">Benjamini O</searchLink>; Sheba Medical Center, Ramat Gan, Israel.<br /><searchLink fieldCode="AU" term="%22Janssens+A%22">Janssens A</searchLink>; UZ Leuven Gasthuisberg, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Levin+MD%22">Levin MD</searchLink>; Albert Schweitzer Hospital, Dordrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Robak+T%22">Robak T</searchLink>; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.<br /><searchLink fieldCode="AU" term="%22Simkovic+M%22">Simkovic M</searchLink>; 4th Department of Internal Medicine-Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Voloshin+S%22">Voloshin S</searchLink>; Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Vorobyev+V%22">Vorobyev V</searchLink>; SP Botkin Moscow City Clinical Hospital, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Yagci+M%22">Yagci M</searchLink>; Gazi Universitesi Tip Fakultesi, Ankara, Türkiye.<br /><searchLink fieldCode="AU" term="%22Ysebaert+L%22">Ysebaert L</searchLink>; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Qi+K%22">Qi K</searchLink>; Janssen Research & Development, Titusville, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Qi+Q%22">Qi Q</searchLink>; Janssen Research & Development, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Sinet+P%22">Sinet P</searchLink>; Janssen Research & Development, Bridgewater, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Parisi+L%22">Parisi L</searchLink>; Janssen Research & Development, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Srinivasan+S%22">Srinivasan S</searchLink>; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA, USA.<br /><searchLink fieldCode="AU" term="%22Schuier+N%22">Schuier N</searchLink>; Janssen Research & Development, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Baeten+K%22">Baeten K</searchLink>; Janssen Research & Development, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Howes+A%22">Howes A</searchLink>; Janssen Research & Development, High Wycombe, UK.<br /><searchLink fieldCode="AU" term="%22Caces+DB%22">Caces DB</searchLink>; Janssen Research & Development, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Kater+AP%22">Kater AP</searchLink>; Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2023 Dec; Vol. 24 (12), pp. 1423-1433. <i>Date of Electronic Publication: </i>2023 Nov 06.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37944541
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(23)00452-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1423
    Titles:
      – TitleFull: Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Niemann CU
      – PersonEntity:
          Name:
            NameFull: Munir T
      – PersonEntity:
          Name:
            NameFull: Moreno C
      – PersonEntity:
          Name:
            NameFull: Owen C
      – PersonEntity:
          Name:
            NameFull: Follows GA
      – PersonEntity:
          Name:
            NameFull: Benjamini O
      – PersonEntity:
          Name:
            NameFull: Janssens A
      – PersonEntity:
          Name:
            NameFull: Levin MD
      – PersonEntity:
          Name:
            NameFull: Robak T
      – PersonEntity:
          Name:
            NameFull: Simkovic M
      – PersonEntity:
          Name:
            NameFull: Voloshin S
      – PersonEntity:
          Name:
            NameFull: Vorobyev V
      – PersonEntity:
          Name:
            NameFull: Yagci M
      – PersonEntity:
          Name:
            NameFull: Ysebaert L
      – PersonEntity:
          Name:
            NameFull: Qi K
      – PersonEntity:
          Name:
            NameFull: Qi Q
      – PersonEntity:
          Name:
            NameFull: Sinet P
      – PersonEntity:
          Name:
            NameFull: Parisi L
      – PersonEntity:
          Name:
            NameFull: Srinivasan S
      – PersonEntity:
          Name:
            NameFull: Schuier N
      – PersonEntity:
          Name:
            NameFull: Baeten K
      – PersonEntity:
          Name:
            NameFull: Howes A
      – PersonEntity:
          Name:
            NameFull: Caces DB
      – PersonEntity:
          Name:
            NameFull: Kater AP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2023 Dec
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1